n the normal heart, reduction of isovolumic contraction and relaxation durations is a physiological response to increase in heart rate (HR). This allows the heart to maintain a constant and controlled balance between the different phases of cardiac cycle for favoring both left ventricular (LV) ejection and filling. 1, 2 We previously evaluated LV function during chronic hypertension and hypertrophy induced by continuous infusion of angiotensin II in pigs. 3 Although no clinical signs of heart failure were present, we observed early and simultaneous maladaptive LV responses to chronotropic and inotropic stimuli that altered diastolic filling time. The maladaptive LV responses displayed as 1 failure of isovolumic contraction and relaxation durations to reduce while HR accelerated and 2 abnormally blunted isovolumic contraction and relaxation responses to dobutamine infusion. In hypertrophied hearts, there is abnormal LV subendocardial blood flow and limited coronary reserve that might fail to meet myocardial oxygen consumption, leading to myocardial ischemia and dysfunction. [4] [5] [6] These observations led us to consider a role of increased HR in the deterioration of LV function during chronic hypertension.
I
n the normal heart, reduction of isovolumic contraction and relaxation durations is a physiological response to increase in heart rate (HR). This allows the heart to maintain a constant and controlled balance between the different phases of cardiac cycle for favoring both left ventricular (LV) ejection and filling. 1, 2 We previously evaluated LV function during chronic hypertension and hypertrophy induced by continuous infusion of angiotensin II in pigs. 3 Although no clinical signs of heart failure were present, we observed early and simultaneous maladaptive LV responses to chronotropic and inotropic stimuli that altered diastolic filling time. The maladaptive LV responses displayed as 1 failure of isovolumic contraction and relaxation durations to reduce while HR accelerated and 2 abnormally blunted isovolumic contraction and relaxation responses to dobutamine infusion. In hypertrophied hearts, there is abnormal LV subendocardial blood flow and limited coronary reserve that might fail to meet myocardial oxygen consumption, leading to myocardial ischemia and dysfunction. [4] [5] [6] These observations led us to consider a role of increased HR in the deterioration of LV function during chronic hypertension.
Accordingly, we investigated the effects of acute selective HR reduction with the I f -channel blocker ivabradine 7 on LV dysfunction in our chronic hypertensive pig model (continuous angiotensin II infusion) 3 because this drug has the advantage that it does not modify atrioventricular or intraventricular conduction, inotropy, and lusitropy in animals and humans. [8] [9] [10] [11] Reduction in HR could facilitate diastolic filling by prolonging the diastolic period, 12, 13 improving arterioventricular coupling, 14 or reducing myocardial ischemia. 15 , 16 Here, we hypothesized that selective HR reduction with ivabradine could restore a normal balance between the different phases of the cardiac cycle by normalizing isovolumic contraction and relaxation times. We also investigated whether ivabradine could avoid deterioration of LV function under dobutamine challenge (ie, a supplemental stress combining positive inotropism and chronotropism).
Methods
The experiments were conducted in accordance with the French regulations concerning the care and use of laboratory animals and were agreed by the local animal ethical committee (ComEth AFSSA-ENVA-UPEC agreement no. 11-0059).
Surgical Instrumentation
Under anesthesia, 19 female pigs (20-30 kg) underwent left thoracotomy. Fluid-filled Tygon catheters were implanted in the descending thoracic aorta, in the left atrium, and in the pulmonary artery for measurement of arterial blood pressure and angiotensin II infusion. A solid-state pressure transducer (Konigsberg Instruments, Pasadena, CA) was introduced into LV. A flow probe (Transonic Systems Inc, Ithaca, NY) was implanted around the aortic root. A pair of piezoelectric crystals was implanted on opposed LV anterior and posterior endocardial surfaces to measure LV internal diameter, and another pair was placed on opposed LV endocardial and epicardial surfaces to measure wall thickness. Two electrodes were fixed on the left atrial appendage for pacing. All catheters and wires were exteriorized between the scapulae. Animals were sedated with diazepam (0.2-0.4 mg/kg IV) for postoperative care. Enrofloxacine (2 mg/kg per day, IM) and long acting amoxicillin (15 mg/kg every 2 days, IM) were administered during 10 days after surgery. Buprenorphine (0.3 mg SC) was administered during 5 days after surgery. The position of all catheters and crystals was confirmed at autopsy, and the left ventricle was weighed.
Hemodynamic Measurements
All hemodynamic data were digitized and analyzed using HEM v4.2 software (Notocord Systems, Croissy sur Seine, France). Aortic and left atrial pressures were measured with P23XL pressure transducers (Becton-Dickinson, Franklin Lakes, NJ). Cardiac output was measured using a T206 blood flowmeter (Transonic Systems Inc, Ithaca, NY). LV pressure was cross-calibrated with the left atrial and aortic pressures. Change in LV pressure over time (dP/dt) was computed from the LV pressure signal. Wall thickening was defined as endsystolic minus end-diastolic wall thicknesses. In some animals, the signals of LV wall thickness, LV internal diameter, and aortic flow were progressively lost during the 4 weeks of protocol because of defective crystals and probes.
LV end diastole was defined at the initiation of the upstroke of LV pressure tracing after atrial contraction and indicated by the initial increase in LV dP/dt. Aortic valve opening and closure were identified by crossing LV and aortic pressure waveforms. Isovolumic contraction time was defined as the time interval between end diastole and aortic valve opening. Ejection time was defined as the time interval between aortic valve opening and closure. Mitral valve opening was identified by crossing LV and atrial pressure waveforms. The isovolumic relaxation period was defined as the period elapsed from aortic valve closure and mitral valve opening. The filling period was computed from the end of isovolumic relaxation to end diastole.
Protocol
The experiments were conducted 2 to 3 weeks after surgery in conscious state (Figure 1) . At day 0, a first set of recordings was performed at baseline and during infusion of dobutamine (10 µg/kg per minute, 5 minutes). These responses were again evaluated after administration of ivabradine (1 mg/kg IV bolus). Recordings were also performed during short sequences of atrial pacing (150 beats/min) to offset HR-reducing properties of ivabradine.
Thereafter, pigs received a continuous infusion of either saline or angiotensin II (30 ng/kg per minute) during 4 weeks using external peristaltic portable pumps as control or to induce hypertension, 3 respectively. The angiotensin II-treated animals developed LV hypertrophy (LV to body weight ratio at 3.9±0.2). At day 28, responses to dobutamine were again evaluated before and after administration of ivabradine (with and without pacing). These recordings were performed 1 hour after stopping angiotensin II infusion to minimize the impact of changes in loading conditions (ie, to evaluate the intrinsic LV contractile properties).
Statistical Analyses
All results are means±SEM. Statistical analysis was performed with StatView version 5.0 (Abacus Concept, Berkeley, CA) using 2-way ANOVA for repeated measures with drug effect, time effect, and time×drug interaction. If needed, individual comparisons were performed by Student t test with Bonferroni correction. Differences were considered significant for P<0.05.
Results

Changes in Hemodynamic and Cycle Time Intervals in Resting Conditions at Day 0 and Day 28
As shown in Table S1 in the online-only Data Supplement, HR was significantly increased by 47% at day 28 versus day 0 in angiotensin II-treated animals, whereas it remained unchanged in control conditions. Concomitantly, mean arterial pressure and systolic LV pressure remained unchanged. In saline-treated animals, none of these parameters was modified at day 28 versus day 0.
Among parameters of cardiac cycle time intervals, total cycle, ejection, and filling times were significantly reduced as a result of increased HR ( Figure 2) . Paradoxically, as shown in Table  and Figure 2 , both isovolumic contraction and relaxation times failed to reduce and remained unchanged. Therefore, the time devoted to isovolumic contraction and relaxation phases during 
Changes in Hemodynamic and Cycle Time Intervals Under Dobutamine Infusion
Hemodynamic parameters and time intervals measured under dobutamine infusion are shown in Tables S1 and S2, respectively. In angiotensin II-treated animals, HR increased by 20% at day 0 and by 11% at day 28. At day 0 but not at day 28, dobutamine lowered mean arterial pressure while systolic LV pressure remained unchanged. LV dP/dt max increased to the same extent at day 28 versus day 0. These responses remained stable between days 0 and 28 in saline-treated animals.
At day 0, under dobutamine infusion, isovolumic contraction and relaxation times decreased by 43% and 20%, respectively, along with the increase in HR. At day 28, isovolumic contraction and relaxation phases failed to adapt properly to dobutamine administration as their responses were blunted (28% and 10%, respectively; Figure 3 ). All these responses remained unchanged between day 0 and day 28 in salinetreated animals.
Selective HR Reduction in Resting Conditions
We next examined whether HR reduction with ivabradine might correct the above mentioned abnormalities. As shown in Table S3 , ivabradine significantly reduced HR by 22% at day 0 in angiotensin II-treated animals. LV peak pressure and LV dP/dt max were not significantly different after ivabradine versus at baseline. Along with HR reduction, LV end-diastolic internal diameter was increased. At day 28, ivabradine produced similar HR reduction (−27%). The effects on LV Regarding time intervals (Table) , administration of ivabradine at day 0 significantly increased the total cycle time while leaving ejection time unchanged. Concomitantly, both isovolumic contraction and relaxation time were significantly reduced (−18% and −14%, respectively; Figure 4 , top). As a consequence, filling time raised by 63% in angiotensin II−treated animals. Saline-treated animals displayed similar responses. At day 28, ivabradine corrected the abnormalities and favorably modified the distribution of time periods by inducing similar effects on isovolumic contraction and relaxation while ejection time remained unchanged but LV filling time was increased.
We next examined the mechanisms of these effects by analyzing these responses under pacing (Figure 4, bottom) . In these conditions, the reduction in isovolumic contraction by ivabradine was abolished both at days 0 and 28, indicating an HR reduction-related mechanism. Interestingly, the reduction in isovolumic relaxation time induced by ivabradine remained under pacing, suggesting a mechanism independent from HR reduction.
Selective HR Reduction During Dobutamine Infusion
As selective HR reduction showed favorable influence on cycle phases at baseline, we next investigated the effects of ivabradine during combined inotropic and chronotropic stress with dobutamine. Ivabradine favorably modified the isovolumic contraction phases in response to dobutamine with significant decreases in isovolumic contraction and relaxation times. As shown in Figure 5 , we also examined the mechanisms of these effects by analyzing these responses under pacing. In these conditions, ivabradine still reduced isovolumic contraction and relaxation times compared with dobutamine alone, suggesting an HR-reducing independent mechanism.
Discussion
In this study, selective HR reduction with acute administration of the I f -channel selective blocker ivabradine reversed the LV maladaptive responses induced by chronic hypertension. In this hypertensive pig model, 3 paradoxical prolonged isovolumic contraction and relaxation times were abolished by selective HR reduction. Their durations were normalized both at baseline and during chronotropic and inotropic stimulation with dobutamine, contributing to the increase in LV filling were evaluated at baseline (circles) and after administration of ivabradine (1 mg/kg; squares) at day 0 (open symbols) and at day 28 before (closed symbols) in angiotensin II-treated pigs. Measurements were performed at spontaneous heart rate (top, n=11) and under controlled heart rate 150 beats/min with atrial pacing (bottom, n=8). *P<0.05 vs corresponding baseline.
time and preservation of LV ejection during chronic hypertension. These results indicate a major role of increased HR in the deterioration of LV function and conversely HR reduction as a mean to preserve LV performance. In addition, pacing the heart to offset HR reduction induced by ivabradine revealed that some of these beneficial effects were still present, suggesting that the improvement of LV function by ivabradine may involve other mechanisms than sole HR reduction. We previously reported that the swine model of chronic hypertension induced by chronic angiotensin II infusion is characterized by preserved ejection, despite simultaneous contraction and relaxation abnormalities which are tightly coupled. 3 We think that this symmetry between contraction and relaxation is in accordance with the concept of the heart as a muscular rather than a hydraulic pump, 17 which explains the presence of subtle contraction alterations although the ejection fraction is preserved. In this study, we confirmed our previous results and observed paradoxically unchanged isovolumic contraction and relaxation times while HR and myocardial contractility were increased by dobutamine. In addition, although ejection time was preserved, LV filling was hampered with the consecutive reduction of its duration.
Several classical physiological reports have clearly shown that a tuned balance exists between HR and cardiac cycle phases to optimize LV ejection. 1, 2, 18 When HR increases, ejection time behaves differently than isovolumic contraction and relaxation or filling times. As previously observed, isovolumic contraction and relaxation as well as filling times proportionally decreased while ejection time is preserved when HR increases >70 beats/min. 9, 19 In pathological situations, this balance is lost, 20 and this can be unmasked under stress conditions. In our experimental conditions, the loss of this balance among cardiac phases was supported by abnormal behavior of isovolumic contraction and relaxation when HR increased.
Because HR has a pivotal role in adapting cardiac output to metabolic demands by tuning all these cardiac phases, it could stand as an elective target in cardiovascular therapeutics. 14, 21 Taking all these considerations into account, we tested the hypothesis that selective HR reduction could normalize the balance between the different phases of the cardiac cycle by examining the effects of acute HR reduction with ivabradine. The choice of HR-reducing strategy deserves to be discussed. In rats with LV hypertrophy, propranolol and verapamil normalize the cardiac gene expression, prevent subcellular remodeling, and attenuate heart dysfunction. 22 In dogs, propranolol reduces systolic and diastolic LV wall stresses, LVdP/dt, and the endo/epi blood flow ratio is no longer reduced below unity during LV hypertrophy. This prevents subendocardial hypoperfusion and subsequent myocardial stunning after exercise. 23 However, in our experimental conditions, acute administration of these types of drugs would have induced major negative inotropic and lusitropic effects as opposed to ivabradine, 9,24 thereby aggravating isovolumic contraction and relaxation abnormalities. Metoprolol did not prevent the reduction in cardiac function and adverse remodeling in mice chronically receiving angiotensin II. 25 Ivabradine has several advantages on other bradycardic agents as it modifies neither LV contractility 8 nor mean ventricular stress during ejection 12 and preserves ventricular relaxation unlike β-blockers. 12, 26, 27 HR reduction exhibits also powerful antiischemic action [28] [29] [30] [31] and increases diastolic coronary perfusion time. 9 In this study, HR reduction with ivabradine decreased isovolumic contraction and relaxation times both in resting conditions and under dobutamine, contributing to favor LV filling and preserve ejection. We chose acute administration to investigate other beneficial properties of ivabradine compared with its known long-term effects like modulation of the inflammatory response and collagen turnover, 25 ,32 atherosclerosis, 33,34 modulation of Measurements were performed at spontaneous heart rate (top, n=11) and under controlled heart rate 150 beats/min with atrial pacing (bottom, n=6). *P<0.05 vs dobutamine alone.
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http://hyper.ahajournals.org/ Downloaded from cardiac apoptosis and LV hypertrophy, 35, 36 or changes in cardiac protein expression. 37 Such acute mechanical effect of ivabradine is in agreement with previous findings, showing that acute HR reduction has a favorable effect on the depressed wall thickening and increased postsystolic wall thickening during postischemic myocardial stunning. 30, 38 Thus it seems that HR reduction with ivabradine allows modifying the balance between the different time phases among the cardiac cycle.
We did not specifically investigate the cellular mechanisms of this beneficial effect. However, under pacing to offset HR reduction, we observed that the beneficial effects of ivabradine on isovolumic contraction were abolished at rest at days 0 and 28, demonstrating that in our experimental conditions, HR reduction is a major determinant of this beneficial mechanism. Interestingly, isovolumic relaxation time was still reduced by ivabradine under controlled HR. Such response was also present under dobutamine with significant reductions in both isovolumic contraction and relaxation phases. This suggests that ivabradine can also modulate LV function through HR reduction independent properties. Pleiotropic effects of ivabradine have been previously reported during ischemia 11, 16 and could be involved in the present experimental conditions. Furthermore, ventricular re-expression of hyperpolarization-activated cyclic nucleotide-gated channels (which carry the If current) occurs in spontaneous hypertensive rats 39 and in ventricular myocytes from failing hearts 40 (ie, possibly contributing to calcium currents and calcium overload). 41 In line with our experimental model, increased LV expression of the If-channels HCN-2 and HCN-4 (hyperpolarization-activated cyclic nucleotide-gated cation channels 2 and 4) has been reported in mice chronically receiving angiotensin II. 25 Therefore, in addition to HR reduction, one could speculate that ivabradine would improve LV function independently from bradycardia by targeting ventricular If-channels and through other pleiotropic effects. It has also been demonstrated that major alterations in excitation-contraction coupling occur in the hypertrophied heart. Ryanodine expression selectively decreases in the subendocardium in dogs with aortic banding and severe LV hypertrophy. 42 This is associated with calcium leak from the sarcoplasmic reticulum as shown by higher calcium sparks rate and reduced SERCA2a (sarcoplasmic reticulum Ca2 + -ATPase 2a) expression. 43 In addition, chronic HR reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FK-binding protein 12/12.6 expression. 37 Altogether, one could, therefore, reasonably speculate that in our experimental conditions, ivabradine improves LV function by modulating excitation-contraction coupling through mechanisms involving HR reduction per se, pleiotropic effects, and targeting increased ventricular If channels. Finally, although we did not measure myocardial oxygen consumption, such HR reduction induced by ivabradine has probably reduced myocardial oxygen consumption. 9, 11 In such high risk myocardium, myocardial ischemia and LV dysfunction because of abnormal subendocardial blood flow and limited coronary reserve have been described. [4] [5] [6] Therefore, by increasing diastolic time, it is likely that coronary perfusion was improved and that HR reduction per se reduced myocardial oxygen demand (ie, favoring LV function). Further investigations are needed to decipher these mechanisms.
Previous experimental studies explored ivabradine in small animals with LV dysfunction induced by diabetes mellitus with db/db mice, 36 hypercholesterolema, 44 or l-thyroxininduced LV hypertrophy 45 and reported favorable effects of chronic HR reduction. In mice chronically receiving angiotensin II, chronic administration of ivabradine improved systolic and diastolic function. This was associated with less cardiac hypertrophy, fibrosis, inflammation, and cardiac apoptosis. 25 In contrast, no beneficial effect of ivabradine has been shown with its long-term administration (3 months of treatment) in rats with aortic banding. In humans, chronic HR reduction for 12 months in allograft recipients reduces LV mass. 46 To our knowledge, our experimental setting is the first one to test the mechanical consequences of acute administration of ivabradine in large animals displaying LV dysfunction during early stage of disease, without major ischemia and heart failure. This may be the basis for further investigations concerning the combination of HR reduction and adrenergic stimulation to overcome the adverse effects of positive inotropic and chronotropic effects on isovolumic phases of cardiac cycle. It is tempting to speculate that administration of ivabradine would improve LV function and tolerance to adrenergic stress in patients with LV dysfunction (eg, exercise). This tight coupling of isovolumic contraction and relaxation observed here further supports the concept of muscular pump 17 as a basis for investigating the heart.
In conclusion, acute HR reduction with ivabradine restores normal LV function in a large animal model of chronic hypertension with preserved ejection and without sign of cardiac failure. Ivabradine allows correcting the maladaptive responses of cardiac cycle phases that occur during chronic hypertension that may jeopardize LV function. This correction is made possible by restoring a normal profile for isovolumic contraction and relaxation both at rest and under adrenergic stress stimulus. This redistribution among the cardiac phases ultimately favors LV filling. Our results suggest that the beneficial effects of acute administration of ivabradine may involve HR reduction dependent and nondependent mechanism.
Perspectives
Chronic hypertension induces both LV diastolic and discrete systolic abnormalities as evidenced by maladaptive responses of isovolumic contraction and relaxation to chronotropic and inotropic stimulation. These 2 periods fail to reduce as HR accelerates, impeding LV filling. Acute HR reduction with ivabradine restores the normal balance between the different time periods of the cardiac cycle both at rest and under adrenergic stimulation. This favors LV filling and preserves LV ejection. These results are limited to this model of hypertension and LV hypertrophy. They support the need to evaluate further the effects of chronic HR reduction during chronic hypertension. 
